Published in Can J Gastroenterol Hepatol on May 01, 2014
Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations. J Crohns Colitis (2015) 0.78
Clinical quality indicators in inflammatory bowel disease. Can J Gastroenterol Hepatol (2014) 0.75
Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Ann Gastroenterol (2016) 0.75
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics (2016) 0.75
Quality Improvement Initiatives in Inflammatory Bowel Disease. Curr Gastroenterol Rep (2017) 0.75
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med (2007) 8.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 5.92
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet (2010) 5.63
Guidelines for the management of inflammatory bowel disease in adults. Gut (2011) 5.42
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. Can J Gastroenterol (2004) 5.09
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology (1993) 4.41
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology (2012) 3.83
Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care (2003) 3.73
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut (1988) 3.66
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol (2012) 3.15
Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2005) 3.01
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut (1992) 2.71
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology (2006) 2.63
A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.57
Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 2.52
Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut (1988) 2.51
Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One (2009) 2.34
Smoking habits and recurrence in Crohn's disease. Gastroenterology (1994) 2.30
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J (1974) 2.24
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics (2012) 2.16
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut (2002) 2.13
Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut (1994) 2.12
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol (2006) 2.12
Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.09
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut (1997) 2.04
Predicting outcome in severe ulcerative colitis. Gut (1996) 1.99
Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study. Gut (1986) 1.87
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 1.85
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2005) 1.84
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology (1995) 1.80
Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 1.78
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol (2009) 1.77
Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) (1982) 1.75
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep (2008) 1.71
A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology (1975) 1.69
A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax (2011) 1.68
Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.67
Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 1.64
Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther (2012) 1.64
Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch Surg (2011) 1.61
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Reduced bone density in patients with inflammatory bowel disease. Gut (1997) 1.56
Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev (2006) 1.51
Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol (2006) 1.49
Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.41
Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol (1998) 1.40
Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology (2001) 1.39
Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol (2009) 1.37
Survey of access to gastroenterology in Canada: the SAGE wait times program. Can J Gastroenterol (2010) 1.37
ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc (2006) 1.36
6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol (2000) 1.34
The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis (2008) 1.33
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33
Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis (2009) 1.30
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol (2011) 1.29
Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci (1992) 1.28
Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer (2003) 1.25
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol (2004) 1.24
American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 1.24
Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2011) 1.24
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology (2008) 1.19
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell (2011) 3.49
Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease. Clin Gastroenterol Hepatol (2008) 2.89
Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm Bowel Dis (2014) 2.76
Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis (2011) 2.62
A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.57
Bowel obstruction following appendectomy: what is the true incidence? Ann Surg (2009) 2.50
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol (2009) 2.39
Boc is a receptor for sonic hedgehog in the guidance of commissural axons. Nature (2006) 2.29
"Sarcoid like" granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med (2010) 2.21
The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis (2013) 2.05
Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis (2014) 2.03
Relationships of Indoor, Outdoor, and Personal Air (RIOPA). Part I. Collection methods and descriptive analyses. Res Rep Health Eff Inst (2005) 1.95
A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol (2009) 1.84
Depression in epilepsy: a systematic review and meta-analysis. Neurology (2012) 1.80
Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta Obstet Gynecol Scand (2010) 1.80
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology (2013) 1.79
Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension (2007) 1.74
The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J Infect Dis (2009) 1.74
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73
Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut (2012) 1.70
Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol (2013) 1.70
Capsule endoscopy in the detection of small-intestinal bleeding in patients supported by a nonpulsatile axial-flow Jarvik 2000 left ventricular assist device. Gastrointest Endosc (2006) 1.61
Axotomy-induced Smad1 activation promotes axonal growth in adult sensory neurons. J Neurosci (2009) 1.61
Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol (2010) 1.59
Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol (2009) 1.56
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Gene targeting using a promoterless gene trap vector ("targeted trapping") is an efficient method to mutate a large fraction of genes. Proc Natl Acad Sci U S A (2005) 1.55
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med (2009) 1.54
Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J (2013) 1.54
Predicting in-hospital mortality in patients undergoing complex gastrointestinal surgery: determining the optimal risk adjustment method. Arch Surg (2011) 1.54
Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ (2011) 1.52
An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci U S A (2002) 1.52
Polycyclic aromatic hydrocarbons in the indoor and outdoor air of three cities in the U.S. Environ Sci Technol (2002) 1.51
Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2010) 1.48
Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2010) 1.48
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis (2011) 1.47
Neurologists warn about link between chiropractic, stroke. CMAJ (2002) 1.45
Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J Crohns Colitis (2012) 1.45
The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv (2012) 1.44
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 1.44
A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol (2009) 1.44
Influence of ambient (outdoor) sources on residential indoor and personal PM2.5 concentrations: analyses of RIOPA data. J Expo Anal Environ Epidemiol (2005) 1.42
Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. Inflamm Bowel Dis (2015) 1.40
Amiodarone rescue therapy for severe decompensated heart failure initially unsuitable for beta-blockers. J Cardiovasc Pharmacol Ther (2003) 1.38
Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci (2008) 1.38
Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology (2008) 1.36
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg (2007) 1.36
Factors associated with hypertension awareness, treatment, and control in Dallas County, Texas. Arch Intern Med (2008) 1.35
Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.31
A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease? Gastroenterology (2012) 1.29
Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis (2014) 1.29
Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol (2011) 1.27
Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm Bowel Dis (2007) 1.26
Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.25
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2011) 1.24
Differences in "bottom-up" and "top-down" neural activity in current and former cigarette smokers: Evidence for neural substrates which may promote nicotine abstinence through increased cognitive control. Neuroimage (2011) 1.23
Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.23
Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res (2012) 1.21
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc (2010) 1.21
The role of TNFalpha in ulcerative colitis. J Clin Pharmacol (2007) 1.20
Streptococcus agalactiae GAPDH is a virulence-associated immunomodulatory protein. J Immunol (2007) 1.18
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis (2013) 1.18
Predicting in-hospital mortality in patients with cirrhosis: results differ across risk adjustment methods. Hepatology (2009) 1.17
Comparing gene discovery from Affymetrix GeneChip microarrays and Clontech PCR-select cDNA subtraction: a case study. BMC Genomics (2004) 1.16
Consideration of multiple chronic diseases in randomized controlled trials. JAMA (2011) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol (2008) 1.13
Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol (2012) 1.12
Differentiation of the lateral compartment of the cochlea requires a temporally restricted FGF20 signal. PLoS Biol (2012) 1.10
Assessment of impairment and activity limitations in the critically ill: a systematic review of measurement instruments and their clinimetric properties. Intensive Care Med (2015) 1.08
Environment and the inflammatory bowel diseases. Can J Gastroenterol (2013) 1.07
Isotretinoin and intestinal inflammation: what gastroenterologists need to know. Gut (2009) 1.07
The desire for hastened death in patients with metastatic cancer. J Pain Symptom Manage (2007) 1.07
Incidence and prevalence of eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr (2013) 1.07
Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management. World J Gastroenterol (2007) 1.07
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. PLoS One (2013) 1.07
The impact of patient education on the quality of inpatient bowel preparation for colonoscopy. Can J Gastroenterol (2010) 1.06
Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. Gastrointest Endosc (2011) 1.06
T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques (2006) 1.06
Open trial of family-based treatment for full and partial anorexia nervosa in adolescence: evidence of successful dissemination. J Am Acad Child Adolesc Psychiatry (2007) 1.06
Safety and efficacy of Hemospray® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol (2014) 1.05
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey. Can J Gastroenterol Hepatol (2015) 1.03
Quality of care delivered to hospitalized inflammatory bowel disease patients. World J Gastroenterol (2013) 1.02
A comparison of continuous and bi-level positive airway pressure non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Crit Care (2006) 1.01
Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol (2008) 1.01
Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet (2003) 1.01
Immediate replacement of fishing with dairying by the earliest farmers of the Northeast Atlantic archipelagos. Proc Biol Sci (2014) 1.01
Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol (2013) 1.00
Fine organic particulate matter dominates indoor-generated PM2.5 in RIOPA homes. J Expo Sci Environ Epidemiol (2006) 1.00
Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis (2015) 1.00
Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg (2011) 0.99